Downregulation of Potential Tumor Suppressor miR-203a by Promoter Methylation Contributes to the Invasiveness of Gastric Cardia Adenocarcinoma

References

• Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am. 2002;11:235–256.
   PubMedGoogle Scholar
• Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978–1992. Int J Epidemiol. 1996;25:941–947.
   PubMed Web of Science ®Google Scholar
• Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17–20.
   PubMed Web of Science ®Google Scholar
• Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–492.
   PubMed Web of Science ®Google Scholar
• Gao Y, Hu N, Han X, Giffen C, Ding T, Goldstein A, et al. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer. 2009;9:269.
   PubMed Web of Science ®Google Scholar
• Friedman RC I, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
   PubMed Web of Science ®Google Scholar
• Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3:83–92.
   PubMedGoogle Scholar
• Trujillo RD, Yue SB, Tang Y, O'Gorman WE, Chen CZ. The potential functions of primary microRNAs in target recognition and repression. EMBO J. 2010;29:3272–3285.
   PubMed Web of Science ®Google Scholar
• Huang JT, Wang J, Srivastava V, Sen S, Liu SM. MicroRNA machinery genes as novel biomarkers for cancer. Front Oncol 2014;4:113.
   PubMedGoogle Scholar
• Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, Wong KF. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med. 2011;9:197.
   PubMed Web of Science ®Google Scholar
• Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. MiR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766–776.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren F, Rong M, Luo Y, Dang Y, Chen G. Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int. 2015;15:62.
   PubMed Web of Science ®Google Scholar
• Lee SA, Kim JS, Park SY, Kim HJ, Yu SK, Kim CS, et al. miR-203 downregulates Yes-1 and suppresses oncogenic activity in human oral cancer cells. J Biosci Bioeng. 2015 ;pii:S1389–S1723(15)00063-8.
   Web of Science ®Google Scholar
• Zhang F, Yang Z, Cao M, Xu Y, Li J, Chen X, et al. MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. Cancer Lett. 2014;342:121–129.
   PubMed Web of Science ®Google Scholar
• Tian L, Li M, Ge J, Guo Y, Sun Y, Liu M, et al. MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 2014;35:5953–5963.
   PubMed Web of Science ®Google Scholar
• Xu M, Gu M, Zhang K, Zhou J, Wang Z, Da J. miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. Diagn Pathol 2015;10:24.
   PubMed Web of Science ®Google Scholar
• Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, et al. mir-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget. 2015;6:8914–8928.
   PubMed Web of Science ®Google Scholar
• Mao L, Zhang Y, Mo W, Yu Y, Lu H. BANF1 is downregulated by IRF1-regulated microRNA-203 in cervical cancer. PLoS One 2015;10:e0117035.
   Google Scholar
• Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, et al. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 2014;5:3770–3784.
   PubMed Web of Science ®Google Scholar
• Tang G, Wu J, Xiao G, Huo L. miR-203 sensitizes glioma cells to temozolomide and inhibits glioma cell invasion by targeting E2F3. Mol Med Rep. 2015;11:2838–2844.
   PubMed Web of Science ®Google Scholar
• Chang X, Sun Y, Han S, Zhu W, Zhang H, Lian S. MiR-203 inhibits melanoma invasive and proliferative abilities by targeting the polycomb group gene BMI1. Biochem Biophys Res Commun. 2015;456:361–366.
   PubMed Web of Science ®Google Scholar
• Zhou X, Xu G, Yin C, Jin W, Zhang G. Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK. Oncotarget. 2014;5:11631–11640.
   PubMed Web of Science ®Google Scholar
• Miao L, Xiong X, Lin Y, Cheng Y, Lu J, Zhang J, et al. MiR-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett. 2014;7:658–662.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Liang H, Wang T, Yan X, Cao M, et al. MiR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. PLoS One. 2013;8:e73985.
   Google Scholar
• Chen Z, Li D, Cheng Q, Ma Z, Jiang B, Peng R, et al. MicroRNA-203 inhibits the proliferation and invasion of U251 glioblastoma cells by directly targeting PLD2. Mol Med Rep. 2014;9:503–508.
   PubMed Web of Science ®Google Scholar
• Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118:5891–5900.
   PubMed Web of Science ®Google Scholar
• Taipaleenmäki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 2015;75:1433–1444.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012;31:58.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2:782–791.
   PubMedGoogle Scholar
• Saini S, Arora S, Majid S, Shahryari V, Chen Y, Deng G, et al. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila). 2011;4:1698–1709.
   PubMed Web of Science ®Google Scholar
• Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25:387–392.
   PubMed Web of Science ®Google Scholar
• Li Z, Du L, Dong Z, Yang Y, Zhang X, Wang L, et al. MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity. PLoS One. 2015;10:e0116170.
   Google Scholar
• Yantiss RK, Goodarzi M, Zhou XK, Rennert H, Pirog EC, Banner BF, et al. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol. 2009;33:572–582.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67:8699–8707.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 2013;30:681.
   PubMed Web of Science ®Google Scholar
• Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, et al. Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol. 2014;133:340–345.
   PubMed Web of Science ®Google Scholar
• Diao Y, Guo X, Jiang L, Wang G, Zhang C, Wan J, et al. miR-203, a tumor suppressor frequently downregulated by promoter hypermethylation in rhabdomyosarcoma. J Biol Chem. 2014;289:529–539.
   PubMed Web of Science ®Google Scholar
• Botezatu A, Goia-Rusanu CD, Iancu IV, Huica I, Plesa A, Socolov D, et al. Quantitative analysis of the relationship between microRNA-124a, −34b and −203 gene methylation and cervical oncogenesis. Mol Med Rep. 2011;4:121–128.
   PubMed Web of Science ®Google Scholar
• Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, et al. Epigenetic inactivation of the hsa-miR-203 in hematological malignancies. J Cell Mol Med. 2011;15:2760–2767.
   PubMed Web of Science ®Google Scholar
• Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, et al. Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet. 2011;20:4025–4040.
   PubMed Web of Science ®Google Scholar
• Yan B, Guo JT, Zhu CD, Zhao LH, Zhao JL. MiR-203b: a novel regulator of MyoD expression in tilapia skeletal muscle. J Exp Biol. 2013;216:447–451.
   PubMed Web of Science ®Google Scholar
• Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–1459.
   PubMed Web of Science ®Google Scholar
• Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–1431.
   PubMed Web of Science ®Google Scholar
• He J, Deng Y, Yang G, Xie W. MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol. 2013;108:121–125.
   PubMed Web of Science ®Google Scholar
• Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:3120–3128.
   PubMed Web of Science ®Google Scholar
• Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, et al. MiR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2012;29:1859–1865.
   PubMed Web of Science ®Google Scholar